|
A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients with Cirrhosis Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients with Cirrhosis conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients with Cirrhosis Clinical research trials and A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients with Cirrhosis healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients with Cirrhosis. A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients with Cirrhosis Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients with Cirrhosis clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients with Cirrhosis condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients with Cirrhosis  A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients with Cirrhosis
A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients with Cirrhosis
For Condition: Hypertension, Portal,Liver Cirrhosis,Esophageal and Gastric Varices
Status: No longer recruiting
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) , Yale University
Synopsis: OBJECTIVES: I. Evaluate the efficacy of a certain drug in preventing intestinal complications in patients with cirrhosis and high blood pressure in the hepatic portal vein. II. Evaluate vein pressure measurements to predict the development of internal bleeding.
Details: PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by participating institution, cirrhosis etiology, and hepatic venous pressure gradient. The dose of oral timolol is titrated over 28 days. Patients are then randomly assigned to daily timolol at the titrated dose or a placebo if successful titration is achieved by day 28, and the final titration dose is maintained for at least 10 days. Timolol is discontinued prior to randomization. Criteria for removal from study include esophageal or gastric varices, significant bleeding or hemorrhage, timolol-induced hepatic encephalopathy, and liver transplantation. Patients are followed every 3 months.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Placebo Control, Efficacy Study
Minimum Age/Maximum Age: 18 Years/74 Years
Genders: Both
Protocol Entry Criteria: - Biopsy-proven cirrhosis of any etiology, including hepatitis B or C. No primary biliary cirrhosis. - Hepatic venous pressure gradient (HVPG) at least 6 mm Hg. - Histologic slides available for review OR liver-spleen scan compatible with cirrhosis if biopsy older than 5 years. Repeat biopsy required if scan incompatible OR HVPG at least 10 mm Hg and any of the following clinical features suggestive of cirrhosis: telangiectasias, palmar erythema, muscle wasting, liver hard and nodular, or splenomegaly, hypoalbuminemia, hyperbilirubinemia, or prolonged prothrombin time, liver-spleen scan with colloid shift to spleen or bone marrow, collaterals visualized by ultrasound or CT. - Gastroesophageal varices negative by endoscopy within 3 months prior to randomization. - Independent verification by 2 endoscopists required. - No ascites requiring specific treatment, e.g., diuretics, paracentesis, peritoneovenous shunt. - Ascites controlled by salt restriction alone allowed. - No splenic or portal vein thrombosis by Doppler-ultrasound. - No primary sclerosing cholangitis. - No radiologically or histologically proven hepatocellular carcinoma. Prior/Concurrent Therapy - At least 1 month since participation in another pharmacologic clinical trial. - At least 1 month since drugs that may affect splanchnic hemodynamics or portal pressure, e.g., beta-blockers, clonidine prazosin, nitrates molsidomine Patient Characteristics - Life expectancy: At least 1 year - Other: Eligibility determined on an individual basis for the following: aortic valve stenosis, atrioventricular block, asthma, chronic obstructive pulmonary disease with positive bronchoconstrictive test, heart failure, hypersensitivity to beta-blockers, insulin-dependent diabetes, organic psychosis, peripheral vascular disease. - No alcohol intake during titration period. - No pregnant women. - Effective contraception required of fertile women.
Total Enrollment: 212
Location and Contact Information:
Overall Study Official:
RobertGroszmann, Study Chair, Yale University
Yale University School of Medicine
New Haven, Connecticut, 06510
United States
Additional Information:
Study ID Numbers: 199/11640; YALESM-6618
Study Start Date: May 1993
Record last reviewed: June 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004641
Other Liver Cirrhosis Studies:
1. A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients with Cirrhosis
Related Studies:
Other Liver Cirrhosis Clinical Trials
Other Connecticut Clinical Trials
Other New Haven Clinical Trials
A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients with Cirrhosis
|
|
|
|
|
|
|
|
